Table 2.

Selinexor doses and dosing schedules

ScheduleDosing interval/weekSelinexor dose, mg/m2Total patientsPatients with NHLPatients with CLLPatients evaluable for responseNo. of DLTsDLT
AM/W/F weeks 1 and 3; M/W weeks 2 and 43111
6111
12333
BLead-in week 12 mg/m2 M/W/F; M/W/F weeks 1 and 3; M/W weeks 2 and 416.82112
233331Grade 4 thrombocytopenia
305325
CM/W30443
352019120
40111
45331
60191914
70222
DM/T234314
EM/Th35222
49333
FOnce weekly803122
GM/W weeks 1 and 2 of 3-week cycle60222
80111
Total7972770
  • Number of patients per dose and dose schedule. Different dose schedules were tested as the toxicity profile of selinexor emerged through clinical experience. A lead-in week of 12 mg/m2 (schedule B) was tested in an attempt to acclimate patients to treatment before receiving the target dose. The lead-in week proved ineffective and was subsequently abandoned in favor of twice-weekly dosing (schedules C, D, and E). High doses of selinexor administered once weekly in a 4-week cycle or twice weekly in a 2-weeks-on, 1-week-off cycle were also tested (schedules F and G). Monday (M), day 1; Tuesday (T), day 2; Wednesday (W), day 3; Thursday (Th), day 4; Friday (F), day 5.